Pacific Capital Partners Ltd Grows Position in Humana Inc. $HUM

Pacific Capital Partners Ltd boosted its position in shares of Humana Inc. (NYSE:HUM) by 35.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,500 shares of the insurance provider’s stock after acquiring an additional 3,500 shares during the quarter. Humana comprises 3.7% of Pacific Capital Partners Ltd’s holdings, making the stock its 12th biggest position. Pacific Capital Partners Ltd’s holdings in Humana were worth $3,458,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HUM. Illinois Municipal Retirement Fund boosted its stake in Humana by 9.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 49,658 shares of the insurance provider’s stock worth $12,920,000 after purchasing an additional 4,351 shares during the period. Bank of New York Mellon Corp increased its stake in Humana by 161.5% in the third quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock valued at $446,911,000 after purchasing an additional 1,060,767 shares during the period. National Pension Service increased its stake in Humana by 2.8% in the third quarter. National Pension Service now owns 189,601 shares of the insurance provider’s stock valued at $49,328,000 after purchasing an additional 5,150 shares during the period. Long Focus Capital Management LLC purchased a new stake in shares of Humana in the third quarter valued at about $34,212,000. Finally, Tejara Capital Ltd acquired a new stake in shares of Humana during the third quarter worth about $1,873,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Down 1.6%

NYSE HUM opened at $166.36 on Tuesday. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $19.97 billion, a P/E ratio of 16.94, a P/E/G ratio of 1.81 and a beta of 0.44. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $315.35. The firm has a 50-day moving average price of $189.58 and a 200 day moving average price of $237.60.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. During the same quarter in the previous year, the company earned ($2.16) EPS. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Friday, March 27th. Humana’s dividend payout ratio is currently 36.05%.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of research reports. Oppenheimer set a $250.00 price target on Humana in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a research report on Thursday, January 22nd. Sanford C. Bernstein reiterated an “outperform” rating and issued a $344.00 target price on shares of Humana in a research note on Tuesday, January 6th. Evercore dropped their target price on Humana from $260.00 to $180.00 in a report on Thursday, February 12th. Finally, Robert W. Baird cut their price target on Humana from $280.00 to $264.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. Seven investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $225.48.

Insider Transactions at Humana

In other Humana news, insider Sanjay K. Shetty bought 810 shares of Humana stock in a transaction on Monday, February 23rd. The stock was bought at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the acquisition, the insider owned 11,657 shares in the company, valued at $2,158,992.97. The trade was a 7.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.